Citius Pharmaceuticals, Inc. (CTXR) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
Analysis Summary
Trailing-twelve-month margins: gross margin 20.0%, operating margin -8.6%, net margin -6.5%.
At the current price of $0.56, CTXR has negative trailing earnings (P/E not meaningful) and an ROE of -67.15%. Market capitalisation stands at $6M.
Balance sheet quality for CTXR: current ratio of 0.6, net cash position of $2.4M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.56 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.21 |
| EV / EBITDA | 0.06 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -67.15% |
| Return on Invested Capital | -67.62% |
| Return on Assets | -32.53% |
| Gross Margin | 19.97% |
| Operating Margin | -863.92% |
| Net Margin | -651.27% |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 0.84 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals, Inc. | $6M | 0.21 | -67.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -2.06% |
| 3 months | +2.49% |
| Year-to-date | -27.93% |
| 1 year | -52.54% |
| 3 years | -96.95% |
| 5 years | -98.92% |
52-Week Range
| 52-week High | $2.19 |
| 52-week Low | $0.47 |
| Avg Volume (90d) | 571K |
Related companies: ADTX · APLM · ATHA · CRIS · DARE · FBLG · ICU
Explore sector: Healthcare · Biotechnology
More sections of CTXR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks